Stephens T C, Adams K, Peacock J H
Br J Cancer. 1984 Jul;50(1):77-83. doi: 10.1038/bjc.1984.141.
A variety of experimental endpoints including excision cell survival, lung colony curability, tumour regrowth delay and i.m. tumour curability following MeCCNU alone and combined with gamma-radiation, were used to define the MeCCNU cell survival curve down to "tumour cure" level in previously untreated i.m. Lewis lung tumours. The survival curve was found to be biphasic, the tumour cells being markedly resistant to MeCCNU at high doses of the drug. Below 10 mg kg-1 the survival curve was exponential through the origin with a D10 of approximately 2 mg kg-1, while above 15 mg kg-1 the D10 was approximately 25 mg kg-1. From linear extrapolation of the terminal part of the cell survival curve to zero drug dose, it appeared that about 1 in 10(5) (or 0.001%) of tumour cells were resistant to MeCCNU.
采用多种实验终点,包括切除后细胞存活、肺集落治愈率、肿瘤再生长延迟以及在单独使用甲基环己亚硝脲(MeCCNU)和联合γ射线照射后肌肉注射肿瘤的治愈率,来确定在先前未治疗的肌肉注射Lewis肺癌中,MeCCNU细胞存活曲线直至“肿瘤治愈”水平。发现存活曲线呈双相性,在高剂量药物时肿瘤细胞对MeCCNU具有明显抗性。低于10mg/kg时,存活曲线从原点开始呈指数形式,D10约为2mg/kg,而高于15mg/kg时,D10约为25mg/kg。从细胞存活曲线末端向零药物剂量进行线性外推,似乎约每10⁵个(或0.001%)肿瘤细胞中有1个对MeCCNU耐药。